Please login to the form below

Not currently logged in
Email:
Password:

Tresiba

This page shows the latest Tresiba news and features for those working in and with pharma, biotech and healthcare.

Novo says real-world data backs its insulin switching

Novo says real-world data backs its insulin switching

Novo says real-world data backs its insulin switching. EU-TREAT study shows Tresiba improved blood glucose control. ... Lantus was found to be neutral on cardiovascular events in the ORIGIN study, while Novo said DEVOTE suggested Tresiba was non-inferior

Latest news

More from news
Approximately 31 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Harnessing commercial innovation Harnessing commercial innovation

    products - such as basal insulin Tresiba and its Ryzodeg and Xultophy combinations. “

  • Interview: Peter Meeus, Novo Nordisk Interview: Peter Meeus, Novo Nordisk

    Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba (insulin degludec), which was approved in Europe at the ... Tresiba has also demonstrated it is just as effective even when

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics